Sorry, you need to enable JavaScript to visit this website.
Skip to main content

This site is intended for US healthcare professionals only.

This site is intended for US healthcare professionals only.

Indication

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Meet BREXAFEMME:

The first and only oral fungicidal treatment for vaginal yeast infections1,2

Image of BREXAFEMME® (ibrexafungerp tablets) pill pack

BREXAFEMME provides rapid relief of burning, itching, and irritation with complete clinical cure in a one-day, oral dose1,2

Meet BREXAFEMME:

The first and only oral fungicidal treatment for vaginal yeast infections1,2

BREXAFEMME provides rapid relief of burning, itching, and irritation with complete clinical cure in a one-day, oral dose1,2

Icon representing the broad-spectrum, fungicidal activity of BREXAFEMME® (ibrexafungerp tablets)

Broad-spectrum activity,*
including fluconazole-resistant,
non-albicans species, such as Candida glabrata1,2

Icon of the BREXAFEMME® (ibrexafungerp tablets) pill pack

One-day oral dosing
that fits your patient’s lifestyle1

Icon of a box labeled Rx

You’ve prescribed the cure.1,2
Now it’s easy for your
patients to find it

*Based on in vitro studies. Clinical significance is unknown.1

MoA=mechanism of action.

SAY NO MORE to vaginal yeast infections.
Prescribe BREXAFEMME today.

SAY NO MORE to vaginal yeast infections. Prescribe BREXAFEMME today.

Indication

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

References

1. BREXAFEMME. Prescribing Information. SCYNEXIS, Inc.; 2021. 2. Data on file. SCYNEXIS, Inc., Jersey City. NJ.

Important Safety Information

Indication

/ / / /
  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp

BREXAFEMME® is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).

Important Safety Information

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp

Read full Important Safety Information